Document is current
Any future updates will be listed below
-
Authors
Tyrakis, Petros A. https://orcid.org/0000-0003-3281-2153
Kampjut, Domen
Steele, Georgina F.
Lindström, H. Jonathan G.
Chirnomas, Deborah
Hopkins, Benjamin D.
Goncalves, Marcus D.
Mukherjee, Siddhartha
Cantley, Lewis C. https://orcid.org/0000-0002-1298-7653
Maddocks, Oliver D. K. https://orcid.org/0000-0002-5551-9091
-
Funding
Funding for this research was provided by:
The research in this paper was funded by Faeth Therapeutics.
- License Information
-
More Information
Article History
Received: 8 November 2024
Revised: 11 April 2025
Accepted: 17 April 2025
First Online: 13 May 2025
Competing interests
: PAT, DK, GFS, HJGL, DC, are or have been employees/paid advisors of Faeth Therapeutics and/or own shares of Faeth Therapeutics. BDH, SM and LCC are shareholders of Faeth Therapeutics. MDG reports consulting/advisory roles with Scorpion Therapeutics and Skye Biosciences; stock or other ownership interests in Faeth Therapeutics; honoraria from Genentech Inc., Novartis AG, Pfizer Inc., and Scorpion Therapeutics; patents, royalties, and other intellectual property with Weill Cornell Medicine. ODKM is a board member, shareholder and paid advisor of Faeth Therapeutics, and is an inventor on patients owned by Faeth Therapeutics and Cancer Research Technology relating to drug/diet combination treatments for cancer.
: In vivo mouse xenograft experiments were performed at a contract research organisation (CRO) according to the approved Institutional Animal Care and Use Committee (IACUC) guidelines following the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) guidance.
